全文获取类型
收费全文 | 262篇 |
免费 | 156篇 |
出版年
2021年 | 3篇 |
2019年 | 2篇 |
2016年 | 3篇 |
2015年 | 5篇 |
2014年 | 3篇 |
2013年 | 2篇 |
2012年 | 3篇 |
2011年 | 9篇 |
2010年 | 4篇 |
2009年 | 3篇 |
2008年 | 7篇 |
2007年 | 12篇 |
2006年 | 7篇 |
2005年 | 6篇 |
2004年 | 10篇 |
2003年 | 2篇 |
2002年 | 6篇 |
2001年 | 6篇 |
2000年 | 14篇 |
1999年 | 10篇 |
1998年 | 5篇 |
1997年 | 10篇 |
1996年 | 8篇 |
1995年 | 5篇 |
1994年 | 14篇 |
1993年 | 10篇 |
1992年 | 22篇 |
1991年 | 25篇 |
1990年 | 22篇 |
1989年 | 16篇 |
1988年 | 15篇 |
1987年 | 14篇 |
1986年 | 11篇 |
1985年 | 14篇 |
1984年 | 4篇 |
1983年 | 9篇 |
1982年 | 5篇 |
1981年 | 9篇 |
1980年 | 4篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1977年 | 9篇 |
1976年 | 6篇 |
1975年 | 10篇 |
1974年 | 17篇 |
1972年 | 3篇 |
1971年 | 5篇 |
1969年 | 7篇 |
1968年 | 3篇 |
1967年 | 2篇 |
排序方式: 共有418条查询结果,搜索用时 584 毫秒
41.
Carboxy-terminal truncations of epidermal growth factor (EGF) receptor affect diverse EGF-induced cellular responses. 总被引:2,自引:0,他引:2
下载免费PDF全文
![点击此处可从《Molecular biology of the cell》网站下载免费的PDF全文](/ch/ext_images/free.gif)
W Li N Hack B Margolis A Ullrich K Skorecki J Schlessinger 《Molecular biology of the cell》1991,2(8):641-649
The binding of epidermal growth factor (EGF) to its receptor induces tyrosine phosphorylation of phospholipase C gamma (PLC gamma), which appears to be necessary for its activation leading to phosphatidyl inositol (PI) hydrolysis. Moreover, EGF-receptor (EGF-R) activation and autophosphorylation results in binding of PLC gamma to the tyrosine phosphorylated carboxy-terminus of the receptor. To gain further insights into the mechanisms and interactions regulating these processes, we have analyzed transfected NIH-3T3 cells expressing two EGF-R carboxy-terminal deletion mutants (CD63 and CD126) with reduced capacity to stimulate PI hydrolysis, Ca2+ rises, and DNA synthesis. In fact, the CD126 mutant lacking 126 carboxy-terminal amino acids, including four tyrosine autophosphorylation sites, was unable to stimulate PI hydrolysis or Ca2+ rise in response to EGF. Surprisingly, EGF binding to the cell lines expressing CD63 or CD126 mutants was followed by similar stimulation of tyrosine phosphorylation of PLC gamma. Our results suggest that although necessary, tyrosine phosphorylation of PLC gamma may not be sufficient for stimulation and PI hydrolysis. It is clear, however, that the carboxy-terminal region of EGF-R is involved in regulation of interactions with cellular targets and therefore plays a crucial role in postreceptor signaling pathways. 相似文献
42.
The effect of fibronectin on myogenesis has been studied in vitro. The addition of purified fibronectin to the myogenic cell line L6 blocks fusion and causes an increase in cell number. The effects of fibronectin could be prevented by the immunoprecipitation of fibronectin from solutions using affinity-purified antifibronectin antibodies. Mild trypsinization of the cells (10 μ/ml trypsin for 20 min) which removes surface fibronectin, causes the rate of fusion to increase when the trypsinization is done just before the cells begin to fuse, day 4 (after the plating of the cells), an inhibition when done on one day earlier, day 3, and has no effect when done after the cells have begun to fuse, day 5. By measuring the binding of rhodamine-labeled antifibronectin antibodies to intact cells, it was found that surface fibronectin increased from day 3 to day 4 and then decreased on day 5. The stimulating effect of trypsin on fusion, therefore, corresponds to the day surface fibronectin reaches a peak. Affinity-purified antifibronectin antibodies were also shown to be capable of enhancing fusion. It is concluded from these results that high levels of fibronectin stimulate events which reduce fusion, whereas the removal of surface fibronectin during critical times either stimulates or reduces fusion. 相似文献
43.
44.
45.
47.
Sanjana Iyengar Paula R. Williamson Jochen Schmitt Lena Johannsen Ian A. Maher Joseph F. Sobanko Todd V. Cartee Daniel Schlessinger Emily Poon Murad Alam 《Trials》2016,17(1)
BackgroundRosacea is a chronic inflammatory disorder affecting millions of individuals worldwide. Diagnosis is based on signs and symptoms with management and treatment aimed to suppress inflammatory lesions, erythema, and telangiectasia. While many clinical trials of rosacea exist, the lack of consensus in outcome reporting across all trials poses a concern. Proper evaluation and comparison of treatment modalities is challenging. In order to address the inconsistencies present, this project aims to determine a core set of outcomes which should be evaluated in all clinical trials of rosacea.Methods/designThis project will utilize a methodology similar to previous core outcome set research. A long list of outcomes will be extracted over four phases: (1) systematic literature review, (2) patient interviews, (3) other published sources, and (4) stakeholder involvement. Potential outcomes will be examined by the Steering Committee to provide further insight. The Delphi process will then be performed to prioritize and condense the list of outcomes generated. Two homogenous groups of physicians and patients will participate in two consecutive rounds of Delphi surveys. A consensus meeting, composed of physicians, patients, and stakeholders, will be conducted after the Delphi exercise to further select outcomes, taking into account participant scores. By the end of the meeting, members will vote and decide on a final recommended set of core outcomes. For the duration of the study, we will be in collaboration with both the Core Outcome Measures in Effectiveness Trials (COMET) and Cochrane Skin Group - Core Outcome Set Initiative (CSG-COUSIN).DiscussionThis study aims to develop a core outcome set to guide assessment in clinical trials of rosacea. The end-goal is to improve the reliability and consistency of outcome reporting, thereby allowing sufficient evaluation of treatment effectiveness and patient satisfaction.
Electronic supplementary material
The online version of this article (doi:10.1186/s13063-016-1554-3) contains supplementary material, which is available to authorized users. 相似文献48.
49.
Ogura K Nagata K Hatanaka H Habuchi H Kimata K Tate S Ravera MW Jaye M Schlessinger J Inagaki F 《Journal of biomolecular NMR》1999,13(1):11-24
Fibroblast growth factors (FGFs) bind to extracellular matrices, especially heparin-like carbohydrates of heparansulfate proteoglycans which stabilize FGFs to protect against inactivation by heat, acid, proteolysis and oxidation. Moreover, binding of FGFs to cell surface proteoglycans promotes to form oligomers, which is essential for receptor oligomerization and activation. In the present study, we determined the solution structure of acidic FGF using a series of triple resonance multi-dimensional NMR experiments and simulated annealing calculations. Furthermore, we prepared the sample complexed with a heparin-derived hexasaccharide which is a minimum unit for aFGF binding. From the chemical shift differences between free aFGF and aFGF-heparin complex, we concluded that the major heparin binding site was located on the regions 110–131 and 17–21. The binding sites are quite similar to those observed for bFGF-heparin hexasaccharide complex, showing that both FGFs recognize heparin- oligosaccharides in a similar manner. 相似文献
50.